Saniona AB Q3 2025 revenue surged to SEK 410.7 million, nearly 57 times higher

Reuters

5 hours ago

Saniona AB Q3 2025 revenue surged to SEK 410.7 million, nearly 57 times higher

Saniona AB reported revenue of SEK 410.7 million for the third quarter (Q3) 2025 and SEK 429.8 million for the nine months ended September 30, 2025. Operating profit reached SEK 359.9 million in Q3 2025, with an operating profit of SEK 317.5 million for the nine-month period. Net profit for Q3 2025 was SEK 329.6 million, while net profit for the nine months ended September 30, 2025 was SEK 326.3 million. Cash and cash equivalents totaled SEK 672.8 million as of September 30, 2025. Basic earnings per share were SEK 2.39 for Q3 2025 and SEK 2.56 for the nine-month period. Diluted earnings per share were SEK 2.35 in Q3 2025 and SEK 2.52 for the nine months ended September 30, 2025. The financial results for the period were positively impacted by an upfront payment from a licensing and partnership agreement with Jazz Pharmaceuticals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saniona AB published the original content used to generate this news brief on November 27, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2586621476"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586621476\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586621476?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 15:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586621476","market":"nz","top_or_hot":-1,"title":"Saniona AB Q3 2025 revenue surged to SEK 410.7 million, nearly 57 times higher","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Saniona AB Q3 2025 revenue surged to SEK 410.7 million, nearly 57 times higher\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Saniona AB reported revenue of SEK 410.7 million for the third quarter (Q3) 2025 and SEK 429.8 million for the nine months ended September 30, 2025. Operating profit reached SEK 359.9 million in Q3 2025, with an operating profit of SEK 317.5 million for the nine-month period. Net profit for Q3 2025 was SEK 329.6 million, while net profit for the nine months ended September 30, 2025 was SEK 326.3 million. Cash and cash equivalents totaled SEK 672.8 million as of September 30, 2025. Basic earnings per share were SEK 2.39 for Q3 2025 and SEK 2.56 for the nine-month period. Diluted earnings per share were SEK 2.35 in Q3 2025 and SEK 2.52 for the nine months ended September 30, 2025. The financial results for the period were positively impacted by an upfront payment from a licensing and partnership agreement with Jazz Pharmaceuticals.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saniona AB published the original content used to generate this news brief on November 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Saniona AB Q3 2025 revenue surged to SEK 410.7 million, nearly 57 times higher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSaniona AB Q3 2025 revenue surged to SEK 410.7 million, nearly 57 times higher\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-27 15:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Saniona AB Q3 2025 revenue surged to SEK 410.7 million, nearly 57 times higher\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Saniona AB reported revenue of SEK 410.7 million for the third quarter (Q3) 2025 and SEK 429.8 million for the nine months ended September 30, 2025. Operating profit reached SEK 359.9 million in Q3 2025, with an operating profit of SEK 317.5 million for the nine-month period. Net profit for Q3 2025 was SEK 329.6 million, while net profit for the nine months ended September 30, 2025 was SEK 326.3 million. Cash and cash equivalents totaled SEK 672.8 million as of September 30, 2025. Basic earnings per share were SEK 2.39 for Q3 2025 and SEK 2.56 for the nine-month period. Diluted earnings per share were SEK 2.35 in Q3 2025 and SEK 2.52 for the nine months ended September 30, 2025. The financial results for the period were positively impacted by an upfront payment from a licensing and partnership agreement with Jazz Pharmaceuticals.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saniona AB published the original content used to generate this news brief on November 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nNDL2ZWX7v:1","article_id":"2586621476","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586621476","pubTimestamp":1764226851,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Saniona AB reported revenue of SEK 410.7 million for the third quarter  2025 and SEK 429.8 million for the nine months ended September 30, 2025. Operating profit reached SEK 359.9 million in Q3 2025, with an operating profit of SEK 317.5 million for the nine-month period. Net profit for Q3 2025 was SEK 329.6 million, while net profit for the nine months ended September 30, 2025 was SEK 326.3 million. Cash and cash equivalents totaled SEK 672.8 million as of September 30, 2025. Basic earnings per share were SEK 2.39 for Q3 2025 and SEK 2.56 for the nine-month period. Diluted earnings per share were SEK 2.35 in Q3 2025 and SEK 2.52 for the nine months ended September 30, 2025. The financial results for the period were positively impacted by an upfront payment from a licensing and partnership agreement with Jazz Pharmaceuticals.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","JAZZ":"爵士制药","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4532":"文艺复兴科技持仓","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC"},"translate_title":"Saniona AB 2025年第三季度收入飙升至4.107亿瑞典克朗，增长近57倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":0.9},"content_text":"Saniona AB Q3 2025 revenue surged to SEK 410.7 million, nearly 57 times higher\n    \n\n        Saniona AB reported revenue of SEK 410.7 million for the third quarter (Q3) 2025 and SEK 429.8 million for the nine months ended September 30, 2025. Operating profit reached SEK 359.9 million in Q3 2025, with an operating profit of SEK 317.5 million for the nine-month period. Net profit for Q3 2025 was SEK 329.6 million, while net profit for the nine months ended September 30, 2025 was SEK 326.3 million. Cash and cash equivalents totaled SEK 672.8 million as of September 30, 2025. Basic earnings per share were SEK 2.39 for Q3 2025 and SEK 2.56 for the nine-month period. Diluted earnings per share were SEK 2.35 in Q3 2025 and SEK 2.52 for the nine months ended September 30, 2025. The financial results for the period were positively impacted by an upfront payment from a licensing and partnership agreement with Jazz Pharmaceuticals.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saniona AB published the original content used to generate this news brief on November 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}